11 results on '"Veld, Peter in't"'
Search Results
2. β-cell replication is increased in donor organs from young patients after prolonged life support
- Author
-
Veld, Peter In't, De Munck, Neelke, Van Belle, Kristien, Buelens, Nicole, Ling, Zhidong, Weets, Ilse, Haentjens, Patrick, Pipeleers-Marichal, Miriam, Gorus, Frans, and Pipeleers, Daniel
- Subjects
Transplantation of organs, tissues, etc. -- Research -- Physiological aspects -- Health aspects ,Young adults -- Health aspects -- Physiological aspects -- Research ,Diabetes -- Complications and side effects -- Care and treatment -- Patient outcomes -- Research ,Pancreatic beta cells -- Research -- Health aspects -- Physiological aspects ,Life support systems (Critical care) -- Patient outcomes -- Health aspects -- Physiological aspects -- Research ,Kidney diseases -- Care and treatment -- Research -- Patient outcomes -- Complications and side effects - Abstract
OBJECTIVE--This study assesses β-cell replication in human donor organs and examines possible influences of the preterminal clinical conditions. RESEARCH DESIGN AND METHODS--β-Cell replication was quantified in a consecutive series of n = 363 human organ donors using double immunohistochemistry for Ki67 and insulin. Uni- and multivariate analysis was used to correlate replication levels to clinical donor characteristics and histopathologic findings. RESULTS--β-Cell replication was virtually absent in most donors, with ≤ 0.1% Ki67-positive β-cells in 72% of donors. A subpopulation of donors, however, showed markedly elevated levels of replication of up to 7.0% Ki67-positive β-cells. β-Cell replication was accompanied by the increased replication of glucagon-, somatostatin-, and CA19.9-positive cells. Prolonged life support, kidney dysfunction, relatively young donor age, inflammatory infiltration, and prolonged brain death before organ retrieval were all found to be significantly associated with an increased level (≥ 90th percentile) of β-cell replication, with the first three risk factors being independent predictors. Increased β-cell replication was most often noted in relatively young donors (≤ 25 years) who received prolonged (≥ 3 days) life support (68%); in contrast, it was rare in donors with a short duration of life support regardless of age (1%). Prolonged life support was accompanied by increased levels of [CD68.sub.+] and LCA/[CD45.sup.+] infiltration in the pancreatic parenchyma. CONCLUSION--These results indicate that preterminal clinical conditions in (young) organ donors can lead to increased inflammatory infiltration of the pancreas and to increased β-cell replication. Diabetes 59:1702-1708, 2010, Human diabetes is a heterogeneous group of disorders with increased glycemia levels and a decreased functional β-cell mass in common. Type 1A diabetes is characterized by a T-cell-mediated autoimmune destruction [...]
- Published
- 2010
- Full Text
- View/download PDF
3. Screening for insulitis in adult autoantibody-positive organ donors
- Author
-
Veld, Peter In't, Lievens, Dirk, De Grijse, Joeri, Ling, Zhidong, Van der Auwera, Bart, Pipeleers-Marichal, Miriam, Gorus, Frans, and Pipeleers, Daniel
- Subjects
Type 1 diabetes -- Risk factors ,Type 1 diabetes -- Diagnosis ,Organ donors -- Health aspects ,Health - Abstract
Antibodies against islet cell antigens are used as predictive markers of type 1 diabetes, but it is unknown whether they reflect an ongoing autoimmune process in islet tissue. We investigated [...]
- Published
- 2007
4. Glibenclamide treatment recruits β-cell subpopulation into elevated and sustained basal insulin synthetic activity
- Author
-
Ling, Zhidong, Wang, Qidi, Stange, Geert, Veld, Peter In't, and Pipeleers, Daniel
- Subjects
Diabetes -- Care and treatment -- Research ,Glibenclamide -- Research ,Pancreatic beta cells -- Health aspects -- Research ,Health - Abstract
Use of sulfonylureas in diabetes treatment is based on their insulin-releasing effect on pancreatic β-cells. Prolonged action is known to degranulate β-cells, but functional consequences have not been examined at the cellular level. This study investigates influences of in vivo (48-h) and in vitro (24-h) glibenclamide treatment on the functional state of the β-cell population. Both conditions decreased cellular insulin content by >50% and caused an elevated basal insulin biosynthetic activity that was maintained for at least 24 h after drug removal. Glibenclamide stimulation of basal insulin synthesis was not achieved after a 2-h exposure; it required a calcium-dependent translational activity and involved an increase in the percent activated β-cells (50% after glibenclamide pretreatment vs. 8% in control cells). The glibenclamide-activated β-cell subpopulation corresponded to the degranulated β-cell subpopulation that was isolated by fluorescence-activated cell sorter on the basis of lower cellular sideward scatter. Glibenclamide pretreatment did not alter cellular rates of glucose oxidation but sensitized β-cells to glucose-induced changes in metabolic redox and insulin synthesis and release. In conclusion, chronic exposure to glibenclamide results in degranulation of a subpopulation of β-cells, which maintain an elevated protein and insulin synthetic activity irrespective of the presence of the drug and of glucose. Our study demonstrates that the in situ β-cell population also exhibits a functional heterogeneity that can vary with drug treatment. Glibenclamide induces degranulated β-cells with a sustained elevated basal activity that might increase the risk for hypoglycemic episodes., Previous studies (1-9) led us to propose that the normal pancreatic β-cell population exhibits intercellular differences that are functionally relevant, in particular for generating the normal dose-response curves to glucose. [...]
- Published
- 2006
5. Growth and functional maturation of [beta]-cells in implants of endocrine cells purified from prenatal porcine pancreas
- Author
-
Bogdani, Marika, Suenens, Krista, Bock, Troels, Pipeleers-Marichal, Miriam, Veld, Peter In't, and Pipeleers, Daniel
- Subjects
Diabetes -- Risk factors ,Diabetes -- Diagnosis ,Diabetes -- Care and treatment ,Insulin -- Health aspects ,Health - Abstract
The development of islet cell transplantation as a cure for diabetes is limited by the shortage of human donor organs. Moreover, currently used grafts exhibit a marginal [beta]-cell mass with an apparently low capacity for [beta]-cell renewal and growth. Although duct-associated nonendocrine cells have often been suggested as a potential source for [beta]-cell production, recent work in mice has demonstrated the role of [beta]-cells in postnatal growth of the pancreatic [beta]-cell mass. The present study investigated whether the [beta]-cell mass can grow in implants that are virtually devoid of nonendocrine cells. Endocrine islet cells were purified from prenatal porcine pancreases (gestation >110 days) and implanted under the kidney capsule of nude mice. [beta]-Cells initially presented with signs of immaturity: small size, low insulin content, undetectable C-peptide release, and an inability to correct hyperglycemia. They exhibited a proliferative activity that was highest during posttransplant week 1 (2.6 and 5% bromodeoxyuridine [BrdU]-positive [beta]-cells 4 and 72 h posttransplant) and then decreased over 20 weeks to rates measured in the pancreas (0.2% BrdU-positive cells). [beta]-Cell proliferation in implants first compensated for [beta]-cell loss during posttransplant week 1 and then increased the [beta]-cell number fourfold between posttransplant weeks 1 and 20. Rates of [alpha]-cell proliferation were only shortly and moderately increased, which explained the shift in cellular composition of the implant ([beta]-cell 40 vs. 90% and [alpha]-cell 40 vs. 7% at the start and posttransplant week 20, respectively). [beta]-Cells progressively matured during the 20 weeks after transplantation, with a twofold increase in cell volume, a sixfold increase in cellular insulin content, plasma C-peptide levels of 1-2 ng/ml, and an ability to correct diabetes. They became structurally organized as homogenous clusters with their secretory vesicles polarized toward fenestrated capillaries. We concluded that the immature [beta]-cell phenotype provides grafts with a marked potential for [beta]-cell growth and differentiation and hence may have a potential role in curing diabetes. Cells with this phenotype can be isolated from prenatal organs; their presence in postnatal organs needs to be investigated., Islet cell transplantation has long been considered as a potential cure for diabetes (1,2). A transplantation protocol has been reported that has achieved a consistent insulin independence that has been [...]
- Published
- 2005
6. Evidence of Tissue Repair in Human Donor Pancreas After Prolonged Duration of Stay in Intensive Care.
- Author
-
Smeets, Silke, Stangé, Geert, Leuckx, Gunter, Roelants, Lisbeth, Cools, Wilfried, De Paep, Diedert Luc, Zhidong Ling, Nico De Leu, Veld, Peter in't, Ling, Zhidong, De Leu, Nico, and In't Veld, Peter
- Subjects
CRITICAL care medicine ,PANCREAS ,INTENSIVE care units ,LEUKOCYTE count ,PANCREATIC diseases ,PANCREATIC physiology ,PROTEIN metabolism ,ANTIGENS ,CELL physiology ,CELL receptors ,COMPARATIVE studies ,LENGTH of stay in hospitals ,MACROPHAGES ,RESEARCH methodology ,MEDICAL cooperation ,NEOVASCULARIZATION ,REGENERATION (Biology) ,RESEARCH ,TUMOR markers ,EVALUATION research - Abstract
M2 macrophages play an important role in tissue repair and regeneration. They have also been found to modulate β-cell replication in mouse models of pancreatic injury and disease. We previously reported that β-cell replication is strongly increased in a subgroup of human organ donors characterized by prolonged duration of stay in an intensive care unit (ICU) and increased number of leukocytes in the pancreatic tissue. In the present study we investigated the relationship between duration of stay in the ICU, M2 macrophages, vascularization, and pancreatic cell replication. Pancreatic organs from 50 donors without diabetes with different durations of stay in the ICU were analyzed by immunostaining and digital image analysis. The number of CD68+CD206+ M2 macrophages increased three- to sixfold from ≥6 days' duration of stay in the ICU onwards. This was accompanied by a threefold increased vascular density and a four- to ninefold increase in pancreatic cells positive for the replication marker Ki67. A strong correlation was observed between the number of M2 macrophages and β-cell replication. These results show that a prolonged duration of stay in the ICU is associated with an increased M2 macrophage number, increased vascular density, and an overall increase in replication of all pancreatic cell types. Our data show evidence of marked levels of tissue repair in the human donor pancreas. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Pancreas and gallbladder agenesis in a newborn with semilobar holoprosencephaly, a case report
- Author
-
Hilbrands, Robert, primary, Keymolen, Kathelijn, additional, Michotte, Alex, additional, Marichal, Miriam, additional, Cools, Filip, additional, Goossens, Anieta, additional, Veld, Peter In’t, additional, De Schepper, Jean, additional, Hattersley, Andrew, additional, and Heimberg, Harry, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Identification of Donor Origin and Condition of Transplanted Islets in Situ in the Liver of a Type 1 Diabetic Recipient
- Author
-
Van Der Torren, Cornelis R., primary, Suwandi, Jessica S., additional, Lee, Dahae, additional, Van't Wout, Ernst-Jan T., additional, Duinkerken, Gaby, additional, Swings, Godelieve, additional, Mulder, Arend, additional, Claas, Frans H. J., additional, Ling, Zhidong, additional, Gillard, Pieter, additional, Keymeulen, Bart, additional, Veld, Peter In't, additional, and Roep, Bart O., additional
- Published
- 2017
- Full Text
- View/download PDF
9. Insulitis in Type 1 Diabetes: A Sticky Problem
- Author
-
Veld, Peter In't, primary
- Published
- 2009
- Full Text
- View/download PDF
10. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.
- Author
-
Vermeij, Joanna, Teugels, Erik, Bourgains, Claire, Ji Xiangming, Veld, Peter in't, Gjislain, Vanessa, Neyns, Bart, and De Grève, Jacques
- Subjects
OVARIAN cancer ,EPIDERMAL growth factor ,HER2 gene ,PROTEIN-tyrosine kinases ,IMMUNOHISTOCHEMISTRY ,CANCER patients - Abstract
Background: The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies. Methods: We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH). Results: The EGFR was expressed in 59% of the cases, with a 2+/3+ staining intensity in 38%. HER2-neu expression was found in 35%, with a 2/3+ staining in 18%. No mutations were found in exons 18--24 of the TK domains of EGFR and HER2-neu. High polysomy of the EGFR gene was observed in 13% of the invasive epthelial cancers and amplification of the HER2-neu gene was found in 10% and correlated with a high expression level by immunohistochemistry. Mutations within the tyrosine kinase domain were not found in the entire TK domain of both genes, but have been found in very rare cases by others. Conclusion: Genomic alteration of the HER2-neu and EGFR genes is frequent (25%) in ovarian cancer. EGFR/HER2-neu targeted therapies should be investigated prospectively and specifically in that subset of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
11. The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
- Author
-
Neyns B, Sadones J, Chaskis C, De Ridder M, Keyaerts M, Veld PI, and Michotte A
- Subjects
- Clinical Trials as Topic, Dacarbazine analogs & derivatives, Dacarbazine therapeutic use, Humans, Procarbazine therapeutic use, Temozolomide, Antineoplastic Agents therapeutic use, Brain Neoplasms drug therapy, Glioma drug therapy
- Abstract
Low-grade gliomas (LGG) are a group of uncommon neuroglial tumors of the central nervous system. They are characterized by a grade I or II according to the WHO classification. Grade I tumors are non-invasive and amenable to surgical resection with curative intent. Diffuse infiltrating LGG (WHO grade II) are tumors with a highly variable prognosis. Curative resection can only rarely be achieved and progression is characterized by transformation into a high-grade glioma (WHO grade III-IV). There are only limited evidence-based treatment recommendations for the management of progressive LGG because of a lack of data from prospective randomized trials. Most often radiotherapy is offered to patients with symptomatic and/or progressive disease. Three randomized trials have failed to demonstrate a survival improvement with either early versus delayed radiation or with a higher dose of radiation. The potential role of chemotherapy for the treatment of LGG has only been addressed in phase II trials. The PCV-chemotherapy regimen is associated with considerable toxicity that limits its applicability. The results with temozolomide (TMZ) chemotherapy have been more promising. Patients with chemosensitive LGG as predicted by heterozygotic loss of chromosomal arms Ip and 19q or methylation of the promoter of the MGMT-gene in the genome of the glioma cells respond to TMZ. Radiotherapy will be compared to chemotherapy asfirst line treatment for LGG in two phase III studies that are planned for by the brain tumor group of the European Organization for Research and Treatment of Cancer (BTG-EORTC) and Radiation Therapy Oncology Group (RTOG).
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.